Journal of Clinical and Translational Endocrinology最新文献

{"title":"GLP-1 receptor agonists: A novel pharmacotherapy for binge eating (Binge eating disorder and bulimia nervosa)? A systematic review","authors":"Laurence Aoun ,&nbsp;Shaza Almardini ,&nbsp;Fares Saliba ,&nbsp;Fadi Haddadin ,&nbsp;Omar Mourad ,&nbsp;Jennifer Jdaidani ,&nbsp;Zeina Morcos ,&nbsp;Ibrahim Al Saidi ,&nbsp;Elie Bou Sanayeh ,&nbsp;Saliba Saliba ,&nbsp;Michel Almardini ,&nbsp;Julie Zaidan","doi":"10.1016/j.jcte.2024.100333","DOIUrl":"https://doi.org/10.1016/j.jcte.2024.100333","url":null,"abstract":"<div><h3>Objective</h3><p>Systematically review evidence on using GLP-1RAs for reducing BEB in BED and BN.</p></div><div><h3>Methods</h3><p>Comprehensive literature search (PubMed and Google Scholar) conducted for studies evaluating GLP-1Ras for BEB. Extracted data on study characteristics, efficacy, and safety.</p></div><div><h3>Results</h3><p>Studies show that GLP-1RAs (liraglutide and dulaglutide) reduce BE frequency and comorbidities in addition to favorable psychiatric side effect profile compared to current options. However, large-scale, blinded placebo-controlled trials are lacking.</p></div><div><h3>Conclusion</h3><p>Early findings suggest promising effects of GLP-1RAs on BEB. However, rigorous clinical trials are needed to firmly establish efficacy, dosing, safety, and comparative effectiveness before considering GLP-1RAs a viable novel approach.</p></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"35 ","pages":"Article 100333"},"PeriodicalIF":3.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214623724000048/pdfft?md5=c4acfc67aff009fa931f433ff8458828&pid=1-s2.0-S2214623724000048-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140016172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of life, daily functioning, and symptoms in hypothyroid patients on thyroid replacement therapy: A Dutch survey","authors":"Ellen Molewijk ,&nbsp;Eric Fliers ,&nbsp;Koen Dreijerink ,&nbsp;Ad van Dooren ,&nbsp;Rob Heerdink","doi":"10.1016/j.jcte.2024.100330","DOIUrl":"https://doi.org/10.1016/j.jcte.2024.100330","url":null,"abstract":"<div><h3>Objective</h3><p>To explore the nature and extent of possible residual complaints among Dutch hypothyroid patients using thyroid replacement therapy, we initiated a comprehensive study measuring health-related quality of life (QoL), daily functioning, and hypothyroidism-associated symptoms in patients and control persons.</p></div><div><h3>Methods</h3><p>An online survey measuring thyroid-specific QoL (ThyPRO), daily functioning, and hypothyroidism-associated symptoms (ThySHI) was distributed among treated hypothyroid patients and control individuals. The advertising text was formulated in an open-ended manner. Patients also provided their most recent thyroid blood values and their thyroid medication.</p></div><div><h3>Results</h3><p>There was a large-sized impairment of QoL (Cohen’s d = 1.04, +93 % ThyPRO score) in hypothyroid patients on thyroid replacement therapy (n = 1195) as compared to controls (n = 236). Daily functioning was significantly reduced i.e., general health (-38 %), problems with vigorous- (+64 %) and moderate activities (+77 %). Almost 80 % of patients reported having complaints despite thyroid medication and in-range thyroid blood values, with 75 % expressing a desire for improved treatment options for hypothyroidism (total n = 1194). Hypothyroid patients experienced 2.8 times more intense hypothyroidism-associated symptoms than controls (n = 865, n = 203 resp). Patients' median reported serum concentrations were: TSH 0.90 mU/L, FT4 17.0 pmol/L, and FT3 2.67 pmol/L, with 52 % having low T3 levels (&lt;3.1 pmol/L). The QoL was not found to be related to age, sex, BMI, menopausal status, stress, serum thyroid parameters, the origin and duration of hypothyroidism, the type of thyroid medication, or the LT4 dose used.</p></div><div><h3>Conclusions</h3><p>Our study revealed major reductions in quality of life and daily functioning, and nearly three times more intense hypothyroidism-associated symptoms in treated hypothyroid patients as compared to controls, despite treatment and largely in-range serum TSH/FT4 concentrations. The QoL was not associated with serum thyroid parameters. We recommend future research into the origin of persisting complaints and the development of improved treatment modalities for hypothyroidism.</p></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"35 ","pages":"Article 100330"},"PeriodicalIF":3.0,"publicationDate":"2024-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214623724000012/pdfft?md5=22eac1ff4c67224c4a9caf1e0ad90398&pid=1-s2.0-S2214623724000012-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139710139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Histopathology of telomerase reverse transcriptase promoter (TERT) mutated indeterminate thyroid nodules","authors":"Jessica O. Pinto ,&nbsp;Masha J. Livhits ,&nbsp;Michael W. Yeh ,&nbsp;Atanas Kaykov ,&nbsp;Joshua P. Klopper ,&nbsp;Richard T. Kloos ,&nbsp;Mohammed Alshalalfa ,&nbsp;Yangyang Hao ,&nbsp;Jing Huang ,&nbsp;Mayumi Endo","doi":"10.1016/j.jcte.2023.100329","DOIUrl":"10.1016/j.jcte.2023.100329","url":null,"abstract":"<div><h3>Objective</h3><p>The objective of this study was to analyze the risk of malignancy and the histopathology of telomerase reverse transcriptase promoter <em>(TERT)</em> mutated cytologically indeterminate thyroid nodules (ITN).</p></div><div><h3>Methods</h3><p>A PUBMED search of molecularly tested ITN was conducted and data on <em>TERT</em> mutated ITN with histopathology correlation were extracted.</p></div><div><h3>Results</h3><p>Twenty-six manuscripts (published between 2014 and 2022) reported on 77 <em>TERT</em> mutated ITN. Sixty-five nodules were malignant (84 %), with 16 (25 %) described with high-risk histopathology, 5 (8 %) described as low-risk, and most without any description. Isolated <em>TERT</em> mutations were malignant in 26/30 ITNs (87 %) with 9 (35 %) described as high risk and none described as low risk. <em>TERT</em> + <em>RAS</em> mutated ITNs were malignant in 29/34 ITNs (85 %) with 3 (10 %) described as high risk and 4 (14 %) described as low risk. Finally, all 5 <em>TERT</em> + <em>BRAF</em>V600E mutated nodules were malignant and 3/5 (60 %) were described as high risk.</p></div><div><h3>Conclusion</h3><p>TERT mutated ITNs have a high risk of malignancy (84 %), and the current data does not show a difference in malignancy rate between isolated <em>TERT</em> mutations and <em>TERT</em> + <em>RAS</em> co-mutated ITNs. When described, <em>TERT</em> + <em>RAS</em> co-mutated ITNs did not have a higher rate of high-risk histopathology as compared to isolated <em>TERT</em> mutated lesions. Most <em>TERT</em> mutated ITNs did not have a description of histopathology risk and the oncologic outcomes, including rate of recurrence, metastases, and disease specific survival, are unknown. Further data is needed to determine if TERT mutated ITNs should be subjected to aggressive initial treatment.</p></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"35 ","pages":"Article 100329"},"PeriodicalIF":3.0,"publicationDate":"2023-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214623723000170/pdfft?md5=11e066f8c8ab519d2f4a73ae11123795&pid=1-s2.0-S2214623723000170-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138608787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utilizing a quality of life tool to examine the presence of fatigue in subjects with diabetes mellitus","authors":"Catherine Nguyen ,&nbsp;Henri K. Parson ,&nbsp;Jordan Pettaway ,&nbsp;Amber Ingram ,&nbsp;Taneisha Sears ,&nbsp;Jason T. Bard ,&nbsp;Steven Forte ,&nbsp;Jennifer A. Wintringham ,&nbsp;Etta Vinik ,&nbsp;Elias S. Siraj ,&nbsp;Carolina M. Casellini","doi":"10.1016/j.jcte.2023.100328","DOIUrl":"https://doi.org/10.1016/j.jcte.2023.100328","url":null,"abstract":"<div><h3>Introduction</h3><p>The prevalence of fatigue in patients with diabetes mellitus (DM) can be as high as 50 %. Physical, mental, and psychosocial components of fatigue negatively impact quality of life (QOL), morbidity and mortality. Several tools have been developed to address fatigue, but none specifically for measuring fatigue in DM. The aim of this study was to assess the impact of diabetes and neuropathy on fatigue using the Norfolk QOL-Fatigue (QOL-F) survey.</p></div><div><h3>Methods</h3><p>605 adult participants from <em>[Anonymous]</em> were recruited (400 subjects with type 1 or type 2 DM and 205 subjects without diabetes (controls)). All subjects completed the Norfolk QOL-F. Demographics, weight, BMI, and duration of diabetes were obtained. The Norfolk QOL-F, a 35-item validated questionnaire, assesses five domains: subjective fatigue, physical and cognitive fatigue, reduced activities, impaired activities of daily living, and depression.</p></div><div><h3>Results</h3><p>Subjects with DM reported significantly higher fatigue total scores (52.63vs33.89, p &lt; 0.0001) and in all five domains when compared to controls. Patients with DM with neuropathy were significantly more fatigued than those without (59.72vs27.83, p &lt; 0.0001). Fatigue scores in patients with DM without neuropathy were similar to controls (27.83vs33.89, p = NS). In multivariate analysis, age, gender, and presence of neuropathy significantly impacted fatigue scores.</p></div><div><h3>Conclusions</h3><p>The Norfolk QOL-F questionnaire can potentially identify the impact of chronic diseases such as diabetes on fatigue. Assessing the different components of fatigue is important for clinicians in improving disease management and outcomes. Further investigations are needed to confirm these observations in specific cohorts with other comorbidities.</p></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"34 ","pages":"Article 100328"},"PeriodicalIF":3.0,"publicationDate":"2023-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214623723000169/pdfft?md5=e82955bf55a2a4f7ba46649fc8861ed5&pid=1-s2.0-S2214623723000169-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134655022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Peripheral sensory neuropathy is associated with circulating angiopoietins in type 2 diabetes patients in Ghana","authors":"Jennifer A. Agyekum ,&nbsp;Kwame Yeboah","doi":"10.1016/j.jcte.2023.100327","DOIUrl":"10.1016/j.jcte.2023.100327","url":null,"abstract":"<div><h3>Objective</h3><p>Peripheral sensory neuropathy (PSN) is a common complication of type 2 diabetes (T2DM) that can lead to frequent ulcerations, lower extremities, and reduced quality of life. Imbalance in the circulating levels of angiogenic growth factors, notably, angiopoietin (Ang)-1, Ang-2 and vascular endothelial growth factor (VEGF) may be among the underlying mechanisms of PSN in T2DM patients. We studied the association between PSN and angiogenic growth factors, Ang-1, Ang-2 and VEGF in T2DM patients in Ghana.</p></div><div><h3>Methods</h3><p>In a case-control study design, PSN was evaluated in 160 patients with T2DM and 108 nondiabetic controls using vibration perception threshold (VPT) and diabetic neurological examination (DNE). The definition of PSN was abnormal VPT (≥25 mV) or the presence of neuropathic symptoms on examination (DNE score &gt; 3). In addition, fasting venous blood samples were collected to measure circulating levels of Ang-1, Ang-2 and VEGF.</p></div><div><h3>Results</h3><p>Compared to non-diabetic controls, patients with T2DM had a higher prevalence of PSN using abnormal VPT (20.6 % vs 2.8 %, p &lt; 0.001) or neuropathic symptoms (35.6 % vs 3.7 %, p &lt; 0.001). Compared to nondiabetic controls, patients with T2DM had increased levels of Ang-2 [597 (274 – 1005) vs 838 (473 – 1241) ng/ml, p = 0.018] and VEGF [48.4 (17.4 – 110.1) vs 72.2 (28 – 201.8), p = 0.025] and decreased Ang-1 levels [41.1 (30 – 57.3) vs 36.1 (24.7 – 42.1) ng/ml, p = 0.01]. In regression analyses, an increase in Ang-1 levels was associated with decreased odds, while an increase in Ang-2 levels was associated with increased odds, of abnormal VPT and neuropathic symptoms in T2DM patients.</p></div><div><h3>Conclusion</h3><p>In our study population, PSN was associated with reduced plasma levels of Ang-1 and increased plasma levels of Ang-2 in patients with T2DM. Therefore, an imbalance of angiopoietins may be associated with PSN in T2DM.</p></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"34 ","pages":"Article 100327"},"PeriodicalIF":3.0,"publicationDate":"2023-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/44/a7/main.PMC10563058.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41222229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The relationship between diabetic ketoacidosis and suicidal or self-injurious behaviour: A systematic review","authors":"Lina Al Alshaikh ,&nbsp;Anne M. Doherty","doi":"10.1016/j.jcte.2023.100325","DOIUrl":"10.1016/j.jcte.2023.100325","url":null,"abstract":"<div><h3>Background</h3><p>It has been suggested that there may be an association between type 1 diabetes (T1DM) and suicide, with one study reporting a rate 11 times that of the general population The aim of this paper was to investigate the association between Diabetic ketoacidosis (DKA: a life-threatening acute complication of T1DM) and suicidal behaviours in people with T1DM.</p></div><div><h3>Methods</h3><p>We performed a search of the following databases: PubMed, PsychInfo, and Embase for papers which explored the association between suicidal behaviours and self-harm with DKA in T1DM. We excluded case reports and review papers.</p></div><div><h3>Results</h3><p>Only three papers explored the relationship between DKA and self-harm. One study found an association between DKA and self-harm in a national cohort of people with type 1 diabetes and schizophrenia. The second found a significant increase in psychiatric admissions for self-harm following an episode of DKA. The third study reported that patients with diabetes and a history of self-harm were at elevated risk of a range of diabetes complications including DKA. These findings indicate an association between DKA and self-harm and support the guidelines in recommending a psychosocial assessment where DKA cannot be explained.</p></div><div><h3>Conclusions</h3><p>This review suggests that DKA is associated with suicidal or self-injurious behaviours. The small number of studies and the seriousness of this issue highlight the importance of further research on this topic, to improve the evidence base for the identification and treatment of risk of suicidal behaviours in people with T1DM.</p></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"34 ","pages":"Article 100325"},"PeriodicalIF":3.0,"publicationDate":"2023-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10568420/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41239773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel interactive text-messaging curriculum for endocrinology board review","authors":"Priyanka Majety ,&nbsp;Ayodele Ajayi ,&nbsp;Anna M. Modest ,&nbsp;Maria Vamvini ,&nbsp;Jason A. Freed","doi":"10.1016/j.jcte.2023.100326","DOIUrl":"10.1016/j.jcte.2023.100326","url":null,"abstract":"<div><h3>Background</h3><p>The ABIM certification exam is one of the measures to ensure that physicians have the clinical skills for good care delivery. The 5-year average pass rate for ABIM Endocrinology exam is 82%. The pass rate significantly decreased to a nadir of 74% in 2021 and 2022, lowest of all medicine subspecialties.</p></div><div><h3>Objectives</h3><p>To assess the feasibility of text messaging curriculum for fellows and its utility in improving their test performance.</p></div><div><h3>Methods</h3><p>In 2021, endocrinology fellows from 51 programs across the country were invited to participate in our curriculum. They completed a pre-test, joined a texting group via Remind application and received 1 multiple choice question daily (total n = 78). After 15 weeks, they completed a post-test and survey. Paired results from pre- and post-test were compared.</p></div><div><h3>Results</h3><p>A total of 89 fellows from 27 programs responded. Of these, 82 fellows, predominantly females (n = 60; 73 %), filled out the pre-test. On an average, 42 fellows (SD = 12) responded to the questions daily and 57 % of them answered the questions within 24 h. Thirty fellows completed the post-test. The median number of correct responses on the pre-test was 5 (IQR 3–6), compared to 8 (IQR 6–9) in the post-test. There was a significant improvement (p-value &lt; 0.0001) in fellows’ performance in the post-test when compared with the pre-test following our intervention.</p></div><div><h3>Conclusions</h3><p>Text-messaging based curriculum for exam preparation is feasible and can improve test performance. Fellows find receiving a daily high yield multiple choice question via text-message as a useful tool for exam preparation.</p></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"34 ","pages":"Article 100326"},"PeriodicalIF":3.0,"publicationDate":"2023-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570572/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41239772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prospective effects of cholecalciferol supplementation on irisin levels in sedentary postmenopausal women: A pilot study","authors":"Luiz Phellipe Dell Aquila ,&nbsp;Armando Morales ,&nbsp;Patricia Moreira ,&nbsp;Maysa Seabra Cendoroglo ,&nbsp;Rosilene Motta Elias ,&nbsp;Maria Aparecida Dalboni","doi":"10.1016/j.jcte.2023.100324","DOIUrl":"10.1016/j.jcte.2023.100324","url":null,"abstract":"<div><h3>Introduction</h3><p>In postmenopausal women, vitamin D deficiency has been associated with disability, low muscle mass and fractures. Irisin is an important myokine that may contribute to the maintenance of muscle and bone density. Vitamin D is associated with the growth and function of muscle tissue through interactions between the vitamin D receptor and PGC-1α and activation of p38/MAPK (mitogen-activated protein kinase) in muscle, a mechanism similar to irisin action. The aim of this pilot study was to evaluate the effects of cholecalciferol supplementation on serum irisin levels in sedentary postmenopausal women with hypovitaminosis D (25(OH)D &lt; 20 ng/mL).</p></div><div><h3>Material and methods</h3><p>80 sedentary postmenopausal women with hypovitaminosis D and low sun exposure were supplemented with cholecalciferol (30,000 IU/month) for 12 months. Calcium, parathyroid hormone, alkaline phosphatase (AP) and irisin levels were measured before and after supplementation.</p></div><div><h3>Results</h3><p>25(OH) vitamin D increased in all participants. Serum levels of irisin increased (from 0.52 ± 0.27 to 0.80 ± 0.53; p &lt; 0.003), accompanied by a decrease in AP (from 80 ± 24 to 66 ± 23; p &lt; 0.001).</p></div><div><h3>Conclusions</h3><p>Restoration of vitamin D status increased serum irisin levels in sedentary postmenopausal women. Whether increased serum irisin levels may have an impact on clinical outcomes deserves further evaluation.</p></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"34 ","pages":"Article 100324"},"PeriodicalIF":3.0,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b0/aa/main.PMC10510082.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41180665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics, staging and outcomes of differentiated thyroid cancer in patients with and without Graves’ disease","authors":"Chaitra Gopinath ,&nbsp;Hanna Crow ,&nbsp;Sujata Panthi ,&nbsp;Leonidas Bantis ,&nbsp;Kenneth D. Burman ,&nbsp;Chitra Choudhary","doi":"10.1016/j.jcte.2023.100321","DOIUrl":"10.1016/j.jcte.2023.100321","url":null,"abstract":"<div><h3>Background</h3><p>The incidence of thyroid cancer has increased over the last three decades with studies showing incidence of thyroid cancer is higher among patients with Graves’ Disease (GD) when compared to Toxic multinodular goiter.¹ We conducted a retrospective study to further investigate characteristics and outcomes in patients with thyroid cancer and GD.</p></div><div><h3>Methods</h3><p>We retrospectively reviewed 62 patients with a diagnosis of Differentiated Thyroid Cancer (DTC). We compared age at diagnosis, type, size of tumor, radioactive iodine (RAI) use, and DTC recurrence amongst patients with GD, non-GD patients. We used Chi-square to test for independence among categorical variables at a nominal level of 0.05; comparison was based on <em>t</em>-test.</p></div><div><h3>Results</h3><p>Out of 62 patients, 29 patients had GD and DTC (47%). 94% had papillary thyroid cancer. Patients with GD were diagnosed with DTC at a younger age (mean 46 years) in comparison to patients without GD (mean 53 years). There was no difference in the type of DTC. Patients with GD had significantly smaller tumor size (mean size 1.035 cm; p value = 0.002), more Stage 1 and 2 compared to patients without GD (p-value = 0.009). Both groups of patients had similar rates of recurrence on follow up and RAI use.</p></div><div><h3>Conclusion</h3><p>We found patients with GD had smaller tumor size, early-stage DTC when compared to patients without GD and potentially favorable prognosis. More data is needed to understand whether this is due to pathogenesis like Graves antibodies promoting tumor formation or merely earlier detection of DTC in GD.</p></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"33 ","pages":"Article 100321"},"PeriodicalIF":3.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/20/b3/main.PMC10400462.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9956318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combined CFTR modulator therapies are linked with anabolic benefits and insulin-sparing in cystic fibrosis-related diabetes","authors":"Fabian Lurquin ,&nbsp;Sophie Gohy ,&nbsp;Michel P. Hermans ,&nbsp;Vanessa Preumont","doi":"10.1016/j.jcte.2023.100320","DOIUrl":"10.1016/j.jcte.2023.100320","url":null,"abstract":"<div><h3>Aims</h3><p>Combined CFTR modulator therapies have dramatically altered pulmonary outcomes in patients with cystic fibrosis (CF). Their impact on glucose metabolism requires further investigations. This study aims to evaluate insulin requirements after initiation of combined CFTR modulator therapy in patients with CF-related diabetes (CFRD) and HOMA indices changes in CF patients without diabetes.</p></div><div><h3>Methods</h3><p>We retrospectively analyzed: 1) the effects of tezacaftor + ivacaftor and elexacaftor + tezacaftor + ivacaftor on FEV₁, weight, BMI, HbA1c, and daily insulin dose, in 17 CFRD patients and 2) the impact of tezacaftor + ivacaftor on HOMA indices in 15 CF patients without diabetes.</p></div><div><h3>Results</h3><p>Age was 37±12y in the CFRD group (70% men), 88% of whom were homozygous for F508del mutation. Diabetes duration was 15±10y. Median duration of combined CFTR modulator therapy was 16 months (IQR: 4) Thirteen patients received tezacaftor + ivacaftor, of whom 9 were switched to elexacaftor + tezacaftor + ivacaftor. Four patients received elexacaftor + tezacaftor + ivacaftor up front. A decrease in insulin needs was noticed in 88% of patients (0.85±0.3 <em>vs</em> 0.71±0.3U/kg/day; <em>p = 0001</em>). Total daily insulin dose decreased from 50±16 to 44±20U/day (<em>p = 0.017</em>). BMI improved (20.9 (IQR: 1.90) <em>vs</em> 22.1 kg/m² (IQR: 3.70); <em>p = 0.014</em>). HbA1c went from 7.3±1.1 to 7.7±1.6% (<em>p = 0.072</em>). Median age was 22y (IQR: 11) in the CF group without diabetes (67% men), 93% of whom were homozygous for F508del mutation. Duration of combined CFTR modulator therapy was 10±5 months. HOMA-B changes were not significant (129.2 (IQR: 84.8) <em>vs</em> 103.5% (IQR: 66.3) nor were HOMA-S changes (from 94±64 to 95±49%). HOMA-BxS decreased from 112±45 to 104±29% (NS). BMI rose from 21.9±3 to 23.1±3.5 kg/m² (<em>p = 0.047</em>). HbA1c was unchanged (5.0±0.5%). FEV₁ improved in both groups (+11% and + 7% of predicted value; <em>p &lt; 0.001</em>; <em>p = 0.013</em>).</p></div><div><h3>Conclusion</h3><p>Combined CFTR modulator therapies are correlated with a decrease in insulin doses and positive effects on BMI and FEV₁. HOMA indices did not change on tezacaftor + ivacaftor among CF patients without diabetes.</p></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"33 ","pages":"Article 100320"},"PeriodicalIF":3.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4d/c0/main.PMC10336243.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9877690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}